Vera Therapeutics (VERA) Cash & Equivalents (2020 - 2026)
Vera Therapeutics' (VERA) quarterly Cash & Equivalents came in at $114.4 million in Q1 2026, up 107.57% YoY from $55.1 million in Q1 2025, and down 67.76% on a QoQ basis from $354.7 million in Q4 2025.
Vera Therapeutics (VERA) Cash & Equivalents (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of Cash & Equivalents data on file, last reported at $114.4 million in Q1 2026.
- Quarterly Cash & Equivalents rose 107.57% year-over-year to $114.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.4 million (up 107.57% YoY) and the FY2025 annual result came in at $354.7 million, up 282.88% from the prior year.
- Cash & Equivalents slipped to $114.4 million in Q1 2026, from $354.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $354.7 million in Q4 2025 to a low of $25.1 million in Q2 2024.
- A 5-year average of $78.0 million and a median of $50.4 million in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 64.64% — and 2025, when it jumped 282.88%.
- Tracing VERA's Cash & Equivalents over 5 years: stood at $43.5 million in 2022, then rose by 5.11% to $45.7 million in 2023, then soared by 102.81% to $92.6 million in 2024, then jumped by 282.88% to $354.7 million in 2025, then sank by 67.76% to $114.4 million in 2026.
- The last three Cash & Equivalents figures came in at $114.4 million (Q1 2026), $354.7 million (Q4 2025), and $57.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | 48.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.88 Mn |
| Mar 31, 2026 | 114.35 Mn |
| Dec 31, 2025 | 354.73 Mn |
| Sep 30, 2025 | 57.77 Mn |
| Jun 30, 2025 | 49.12 Mn |
| Mar 31, 2025 | 55.09 Mn |
| Dec 31, 2024 | 92.65 Mn |
| Sep 30, 2024 | 27.26 Mn |
| Jun 30, 2024 | 25.09 Mn |
| Mar 31, 2024 | 69.11 Mn |
| Dec 31, 2023 | 45.68 Mn |
| Sep 30, 2023 | 27.44 Mn |
| Jun 30, 2023 | 33.89 Mn |
| Mar 31, 2023 | 137.39 Mn |
| Dec 31, 2022 | 43.46 Mn |
| Sep 30, 2022 | 30.48 Mn |
| Jun 30, 2022 | 50.43 Mn |
| Mar 31, 2022 | 111.51 Mn |
| Dec 31, 2021 | 79.67 Mn |
| Sep 30, 2021 | 86.19 Mn |